XML 42 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions and Divestitures (Narrative) (Details)
$ / shares in Units, $ in Millions
1 Months Ended 3 Months Ended
Apr. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
right
$ / shares
Feb. 28, 2022
USD ($)
Mar. 31, 2023
USD ($)
Mar. 31, 2022
USD ($)
Business Acquisition [Line Items]          
Acquired in-process research and development (Note 3)       $ 105.0 $ 165.6
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Olanzapine Portfolio | Subsequent Event          
Business Acquisition [Line Items]          
Cash proceeds $ 1,050.0        
Additional cash proceeds 305.0        
Milestone payment received 50.0        
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Baqsimi® | Subsequent Event          
Business Acquisition [Line Items]          
Cash proceeds 500.0        
Additional cash proceeds 125.0        
Milestone payment received $ 450.0        
BioMarin Pharmaceutical Inc          
Business Acquisition [Line Items]          
Acquired IPR&D expense     $ 110.0    
Akouos Acquisition          
Business Acquisition [Line Items]          
Business acquisition, share price (in dollars per share) | $ / shares   $ 12.50      
Cash paid, net of cash acquired   $ 327.2      
Consideration transferred, number of contingent value rights | right   1,000,000      
Contingent value right, additional price per share (up to) (in dollars per share) | $ / shares   $ 3,000,000.00      
Contingent value right, additional price per share, aggregate amount   $ 122.0